The NIQ of lopinavir is predictive of a 48-week virological response in highly treatment-experienced HIV-1-infected subjects treated with a lopinavir/ritonavir-containing regimen

Antonella Castagna, Nicola Gianotti, Laura Galli, Anna Danise, Hamid Hasson, Enzo Boeri, Richard Hoetelmans, David Nauwelaers, Adriano Lazzarin

Research output: Contribution to journalArticle

Abstract

Objective: To investigate the normalized inhibitory quotient (NIQ) of lopinavir (LPV) as a predictor of 48-week virological responses to a lopinavir/ritonavir (LPV/RTV)-containing regimen in highly treatment-experienced patients. Design: We calculated the NIQ for 59 patients who completed 48 weeks' treatment and assessed the factors predicting a week-48 virological response. Methods: The NIQ was calculated by dividing each subject's IQ (LPV C trough/fold change in LPV susceptibility, as assessed by Virtua/Phenotype™) by a reference IQ (mean population LPV C trough/fold change in LPV IC50, as assessed by Virtual Phenotype™). HIV-1 RNA was assessed by NASBA (quantification limit: 80 copies/ml). The general linear model and multiple logistic regression, respectively, were used to estimate the independent predictors of a change in viral load and HIV-1 RNA 10 copies/ml, respectively. The median NIQ was 2.2 (0.5-14). At week 48, the median decrease in HIV-1 RNA was 1.4 (0.59-2.79) log10 copies/ml (P

Original languageEnglish
Pages (from-to)537-543
Number of pages7
JournalAntiviral Therapy
Volume9
Issue number4
Publication statusPublished - Aug 2004

Fingerprint

Lopinavir
Ritonavir
HIV-1
RNA
Therapeutics
Self-Sustained Sequence Replication
Phenotype
Viral Load
Inhibitory Concentration 50
Linear Models
Logistic Models
Population

ASJC Scopus subject areas

  • Pharmacology

Cite this

The NIQ of lopinavir is predictive of a 48-week virological response in highly treatment-experienced HIV-1-infected subjects treated with a lopinavir/ritonavir-containing regimen. / Castagna, Antonella; Gianotti, Nicola; Galli, Laura; Danise, Anna; Hasson, Hamid; Boeri, Enzo; Hoetelmans, Richard; Nauwelaers, David; Lazzarin, Adriano.

In: Antiviral Therapy, Vol. 9, No. 4, 08.2004, p. 537-543.

Research output: Contribution to journalArticle

@article{d975800780434072bc42de5c9b36a79e,
title = "The NIQ of lopinavir is predictive of a 48-week virological response in highly treatment-experienced HIV-1-infected subjects treated with a lopinavir/ritonavir-containing regimen",
abstract = "Objective: To investigate the normalized inhibitory quotient (NIQ) of lopinavir (LPV) as a predictor of 48-week virological responses to a lopinavir/ritonavir (LPV/RTV)-containing regimen in highly treatment-experienced patients. Design: We calculated the NIQ for 59 patients who completed 48 weeks' treatment and assessed the factors predicting a week-48 virological response. Methods: The NIQ was calculated by dividing each subject's IQ (LPV C trough/fold change in LPV susceptibility, as assessed by Virtua/Phenotype™) by a reference IQ (mean population LPV C trough/fold change in LPV IC50, as assessed by Virtual Phenotype™). HIV-1 RNA was assessed by NASBA (quantification limit: 80 copies/ml). The general linear model and multiple logistic regression, respectively, were used to estimate the independent predictors of a change in viral load and HIV-1 RNA 10 copies/ml, respectively. The median NIQ was 2.2 (0.5-14). At week 48, the median decrease in HIV-1 RNA was 1.4 (0.59-2.79) log10 copies/ml (P",
author = "Antonella Castagna and Nicola Gianotti and Laura Galli and Anna Danise and Hamid Hasson and Enzo Boeri and Richard Hoetelmans and David Nauwelaers and Adriano Lazzarin",
year = "2004",
month = "8",
language = "English",
volume = "9",
pages = "537--543",
journal = "Antiviral Therapy",
issn = "1359-6535",
publisher = "International Medical Press Ltd",
number = "4",

}

TY - JOUR

T1 - The NIQ of lopinavir is predictive of a 48-week virological response in highly treatment-experienced HIV-1-infected subjects treated with a lopinavir/ritonavir-containing regimen

AU - Castagna, Antonella

AU - Gianotti, Nicola

AU - Galli, Laura

AU - Danise, Anna

AU - Hasson, Hamid

AU - Boeri, Enzo

AU - Hoetelmans, Richard

AU - Nauwelaers, David

AU - Lazzarin, Adriano

PY - 2004/8

Y1 - 2004/8

N2 - Objective: To investigate the normalized inhibitory quotient (NIQ) of lopinavir (LPV) as a predictor of 48-week virological responses to a lopinavir/ritonavir (LPV/RTV)-containing regimen in highly treatment-experienced patients. Design: We calculated the NIQ for 59 patients who completed 48 weeks' treatment and assessed the factors predicting a week-48 virological response. Methods: The NIQ was calculated by dividing each subject's IQ (LPV C trough/fold change in LPV susceptibility, as assessed by Virtua/Phenotype™) by a reference IQ (mean population LPV C trough/fold change in LPV IC50, as assessed by Virtual Phenotype™). HIV-1 RNA was assessed by NASBA (quantification limit: 80 copies/ml). The general linear model and multiple logistic regression, respectively, were used to estimate the independent predictors of a change in viral load and HIV-1 RNA 10 copies/ml, respectively. The median NIQ was 2.2 (0.5-14). At week 48, the median decrease in HIV-1 RNA was 1.4 (0.59-2.79) log10 copies/ml (P

AB - Objective: To investigate the normalized inhibitory quotient (NIQ) of lopinavir (LPV) as a predictor of 48-week virological responses to a lopinavir/ritonavir (LPV/RTV)-containing regimen in highly treatment-experienced patients. Design: We calculated the NIQ for 59 patients who completed 48 weeks' treatment and assessed the factors predicting a week-48 virological response. Methods: The NIQ was calculated by dividing each subject's IQ (LPV C trough/fold change in LPV susceptibility, as assessed by Virtua/Phenotype™) by a reference IQ (mean population LPV C trough/fold change in LPV IC50, as assessed by Virtual Phenotype™). HIV-1 RNA was assessed by NASBA (quantification limit: 80 copies/ml). The general linear model and multiple logistic regression, respectively, were used to estimate the independent predictors of a change in viral load and HIV-1 RNA 10 copies/ml, respectively. The median NIQ was 2.2 (0.5-14). At week 48, the median decrease in HIV-1 RNA was 1.4 (0.59-2.79) log10 copies/ml (P

UR - http://www.scopus.com/inward/record.url?scp=4344707647&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4344707647&partnerID=8YFLogxK

M3 - Article

C2 - 15456085

AN - SCOPUS:4344707647

VL - 9

SP - 537

EP - 543

JO - Antiviral Therapy

JF - Antiviral Therapy

SN - 1359-6535

IS - 4

ER -